141 related articles for article (PubMed ID: 24920908)
1. Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
Zhang J; Li M; Liu Z; Wang L; Liu Y; Zhang N
Int J Nanomedicine; 2014; 9():2741-51. PubMed ID: 24920908
[TBL] [Abstract][Full Text] [Related]
2. The in vitro anti-tumor efficacy and the pharmacokinetics of N3-o-toluyl-fluorouracil loaded nanosuspension (TFu-LNS).
Li M; Zhang J; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2013 May; 9(5):801-10. PubMed ID: 23802409
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
Sun W; Zhang N; Li A; Zou W; Xu W
Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
[TBL] [Abstract][Full Text] [Related]
4. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
5. Release mechanism studies on TFu nanoparticles-in-microparticles system.
Sun W; Zhang N; Li X
Colloids Surf B Biointerfaces; 2012 Jun; 95():115-20. PubMed ID: 22424827
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Liu J; Li X; Cheng YN; Cui SX; Chen MH; Xu WF; Tian ZG; Makuuchi M; Tang W; Qu XJ
Eur J Pharmacol; 2007 Nov; 574(1):1-7. PubMed ID: 17904544
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.
Liu J; Xu WF; Cui SX; Zhou Y; Yuan YX; Chen MH; Wang RH; Gai RY; Makuuchi M; Tang W; Qu XJ
World J Gastroenterol; 2006 Nov; 12(42):6766-70. PubMed ID: 17106923
[TBL] [Abstract][Full Text] [Related]
8. Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo.
Pang X; Wang T; Jiang D; Mu W; Zhang B; Zhang N
Int J Nanomedicine; 2019; 14():2543-2555. PubMed ID: 31114190
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration.
Sun W; Zou W; Huang G; Li A; Zhang N
J Drug Target; 2008 Jun; 16(5):357-65. PubMed ID: 18569280
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery.
Liu C; Liu D; Bai F; Zhang J; Zhang N
Drug Deliv; 2010 Jul; 17(5):352-63. PubMed ID: 20387993
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.
Alanazi SA; Harisa GI; Badran MM; Alanazi FK; Elzayat E; Alomrani AH; Al Meanazel OT; Al Meanazel AT
Bioengineered; 2021 Dec; 12(1):914-926. PubMed ID: 33678142
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition.
Alanazi SA; Harisa GI; Badran MM; Haq N; Radwan AA; Kumar A; Shakeel F; Alanazi FK
Curr Drug Deliv; 2020; 17(10):898-910. PubMed ID: 32072911
[TBL] [Abstract][Full Text] [Related]
14. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
[TBL] [Abstract][Full Text] [Related]
15. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
Cheng M; Chen H; Wang Y; Xu H; He B; Han J; Zhang Z
Int J Nanomedicine; 2014; 9():695-710. PubMed ID: 24493926
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of etoposide-loaded lipid-based nanosuspensions for high-dose treatment of lymphoma.
Yin X; Han L; Mu S; Mu W; Liang S; Wang T; Liu Y; Zhang N
Nanomedicine (Lond); 2019 Jun; 14(11):1403-1427. PubMed ID: 31180263
[No Abstract] [Full Text] [Related]
17. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy.
Wang L; Li M; Zhang N
Int J Nanomedicine; 2012; 7():3281-94. PubMed ID: 22802688
[TBL] [Abstract][Full Text] [Related]
18. Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.
AlQahtani SA; Harisa GI; Badran MM; AlGhamdi KM; Kumar A; Salem-Bekhit MM; Ahmad SF; Alanazi FK
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):989-996. PubMed ID: 30873877
[TBL] [Abstract][Full Text] [Related]
19. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Varshosaz J; Hassanzadeh F; Sadeghi H; Khadem M
J Liposome Res; 2012 Sep; 22(3):224-36. PubMed ID: 22385296
[TBL] [Abstract][Full Text] [Related]
20. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
